Article
Supreme Court Clarifies Standard For Induced Infringement In Hikma v. Amarin
In a unanimous decision handed down today, the Supreme Court delivered a tactical victory for Hikma, and a measure of guidance for other generic manufacturers. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Court held that drug manufacturer Amarin, the reference product sponsor, failed to state a claim for active inducement of patent infringement under 35 U.S.C. § 271(b).
Mintz